ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Transcriptomic correlates of ceftazidime-avibactam collateral sensitivity in tigecycline-resistant NDM-producing enterobacter cloacae complex.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeCarbapenem-resistant Enterobacter cloacae complex (CRECC) has become an increasingly important pathogen in healthcare-associated infections, with limited treatment options and a high mortality rate. As reports of antimicrobial resistance continue to rise, tigecycline (TGC) and ceftazidime-avibactam (CZA) have emerged as the last-line therapies for CRECC infections. The aim of this study was to investigate collateral sensitivity to ceftazidime-avibactam following the acquisition of tigecycline resistance in NDM-producing CRECC, and to explore the transcriptional changes associated with this phenomenon and propose potential mechanistic hypotheses.
methodsAntimicrobial susceptibility profiles were determined using the broth microdilution method, and changes in colony morphology were analyzed. Transcriptomic sequencing was performed to characterize global gene expression alterations associated with antimicrobial resistance, and an in vivo Galleria mellonella infection model was used to assess the virulence of the mutant strains.
resultsBoth drug-resistant mutants displayed a stable mucoid phenotype with marked collateral susceptibility to CZA, with minimum inhibitory concentrations decreasing from greater than 128 mg/L to 0.5-1 mg/L. Compared with the parental strains, these mutants showed thickened cell surface structures, impaired growth, reduced serum tolerance, and significantly attenuated virulence in the Galleria mellonella infection model. Transcriptomic analysis revealed marked downregulation of metallo-β-lactamase-related genes at the transcriptional level.
conclusionIn this study of two clinical isolates, collateral sensitivity to CZA was associated with transcriptional downregulation of bla
Indexed as
Identifiers
42185701What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.